<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610401</url>
  </required_header>
  <id_info>
    <org_study_id>Metformin-FMD 001</org_study_id>
    <nct_id>NCT01610401</nct_id>
  </id_info>
  <brief_title>The Metformin-FMD Trial</brief_title>
  <acronym>MetFMD</acronym>
  <official_title>Can Metformin Prevent Endothelial Ischemia and Reperfusion Injury? The Metformin-FMD Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In acute myocardial infarction early restoration of coronary blood flow is the most effective
      strategy to limit infarct-size. Paradoxically, reperfusion itself also aggravates myocardial
      injury and contributes to final infarct size, a process termed 'reperfusion injury'. Ischemia
      and reperfusion (IR)-induced endothelial dysfunction seems to play a pivotal role in this
      process, resulting in vasoconstriction and reduced blood flow to the already ischemic tissue.
      Recently, it has been shown that the glucose-lowering drug metformin is able to limit
      IR-injury in murine models of myocardial infarction, probably by increased formation of the
      endogenous nucleoside adenosine. In the current research proposal, the investigators aim to
      translate this finding to the human in vivo situation, using flow-mediated dilation (FMD) of
      the brachial artery as a well-validated model of (endothelial) IR-injury.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin-FMD trial: The effect of pretreatment with metformin on FMD of the brachial artery after forearm ischemia and reperfusion.</measure>
    <time_frame>approx. 6 months</time_frame>
    <description>Metformin-FMD trial: To study the effect of oral pretreatment with metformin (500 mg three times ad ay for 3 days) on flow mediated dilation of the brachial artery after 20 minutes of forearm ischemia and 20 minutes of reperfusion in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Control trial: the effect of caffeine on the protective effect of metformin on FMD after ischemia and reperfusion.</measure>
    <time_frame>approx. 6 months</time_frame>
    <description>Control trial: when metformin displays a protective effect on endothelial function, we will conduct a second experiment to study whether caffeine, an adenosine receptor antagonist, attenuates the protective effect of metformin on flow mediated dilation after 20 minutes of ischemia and 20 minutes of reperfusion in healthy volunteers.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Pretreatment with metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pretreatment with metformin 500 mg three times a day for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No pretreatment.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pretreatment with Metformin/caffeine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No metformin, only pretreatment with caffeine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin 500 mg three times a day, for 3 days</description>
    <arm_group_label>Pretreatment with metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretreatment with metformin in combination of infusion of caffeine.</intervention_name>
    <description>Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement</description>
    <arm_group_label>Pretreatment with Metformin/caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No pretreatment with metformin in combination with infusion of caffeine</intervention_name>
    <description>No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).</description>
    <arm_group_label>No metformin, only pretreatment with caffeine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-50 years

          -  Written informed consent

        Exclusion Criteria:

          -  Smoking

          -  Hypertension (in supine position: systolic BP &gt; 140 mmHg, diastolic BP &gt; 90 mmHg)

          -  Hyperlipidaemia (fasting total cholesterol &gt; 5.5 mmol/L or random &gt; 6.5 mmol/L)

          -  Diabetes Mellitus (fasting glucose &gt; 7.0 mmol/L or random glucose &gt; 11.0 mmol/L)

          -  History of any cardiovascular disease

          -  Concomitant use of medication

          -  Renal dysfunction (MDRD &lt; 60 ml/min)

          -  Professional athletes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Riksen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G.A. Rongen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D.H. Thijssen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

